Share page on LinkedIn

Financial Times Global Pharmaceutical and Biotechnology Conference

8 – 10 November, 2021 Online event

Sustaining innovation and collaboration beyond the pandemic

The Global Pharmaceutical and Biotechnology Conference is the essential annual event to stay up to date with innovation and growth across the sector. Leaders in life sciences from around the world will discuss the latest trends in areas such as drug discovery, clinical trials and market access, exploring new frontiers for business and for healthcare.

Featured speakers include:

Bill Anderson, CEO, Roche Pharmaceuticals

Mikael Dolsten, CSO & President, Worldwide Research, Development and Medical, Pfizer

Greg Friberg, VP, Medical Affairs, Amgen

Lars Fruergaard Jørgensen, President and CEO, Novo Nordisk

Susan Galbraigh, Executive VP, Oncology Research and Development, AstraZeneca

Samit Hirawat, Executive VP, Chief Medical Officer, Global Drug Development, BMS

Paul Hudson, CEO, Sanofi

David Loew, CEO, Ipsen

John Oyler, Chairman and CEO, BeiGene

Andrew Plump, President of Research and Development, Takeda

Judy Stewart, Senior VP, Head of US Vaccines, GlaxoSmithKline

Marie-France Tschudin, President, Novartis Pharmaceuticals

ICON speakers:

Kim Boericke

Kim Boericke

President, Commercialisation and Outcomes Services

  • Fireside Chat: Decentralised Clinical Trials - 9 November, 14:10 PM - 14:30 PM GMT
  • Panel: Digital tools to build resilience in clinical trials - 9 November, 14:40 PM -15:25 PM GMT 

The potential for drug development to evolve through digital transformation is vast, and nowhere more so than in clinical trials. But integrating enabling technologies in some areas may be challenging. 

Anthony Costello - SVP, President of Patient Cloud, Medidata

John Reites - CEO, THREAD

Lauren Bataille - Head, Medical Capabilities, Novartis

Moderator: Donato Paolo Mancini - Pharmaceuticals Reporter Financial Times

Gerard Quinn

Gerard Quinn

Vice President, Innovation and Informatics

  • Panel: Transforming early-stage R&D with AI and digital innovation - 9 November, 10:40 AM -11:25 AM GMT

The scope for applying digital tools in early research is growing rapidly. New modes of discovery and advances in analytical power hold great potential. But complex technologies are not always reliable so building trust and understanding will be crucial.   

Faisal Farooq - Head of Digital Health and Precision Medicine Qatar Foundation

Céline Ulmann - Head of R&D Digital, Almirall

Nadeem Sarwar - Global Head, Genomic Strategies and Global Head, Digital Therapeutics Strategies, Eisai

Moderator: Clive Cookson, Science Editor Financial Times